top of page
Use of Long-Acting Injectables
Presented By:
Kara Dempster, MD, MSC, FRCPC
Psychiatrist, Nova Scotia Early Psychosis Program
Assistant Professor, Department of Psychiatry, Dalhousie University
Halifax, NS
Originally presented as part of the 2025 EPI Experts Webinar Series
Learning Objectives:
-
Establish the importance of relapse prevention in early phase psychosis
-
Highlight the importance of LAI use for relapse prevention
-
Review the rates of LAI use in Canada
-
Identify when an LAI is indicated
-
Discuss an approach to choosing an LAI
-
Introduce new and emerging LAI treatments
-
Establish how to guide discussions around LAI treatment
This initiative has been sponsored in part by Abbvie, Bausch, HLS Therapeutics, Lundbeck, Janssen, Otsuka, and Teva through educational grants.
bottom of page